4-Amino-1-pentylpyrimidin-2-one | 1021515-20-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4-Amino-1-pentylpyrimidin-2-one
• CAS: 1021515-20-7
• 化学式: C₉H₁₅N₃O
• 分子量: 181.238
• InChiKey: QQXFWDJRQZZGOM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  58.7
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-Amino-1-pentylpyrimidin-2-one 、 以 氯仿 为溶剂， 反应 18.0h， 生成 pent-4-enyl (2S)-2-[(2-oxo-1-pentylpyrimidin-4-yl)carbamoylamino]-3-phenylpropanoate
  参考文献：
  名称：

  Hydrogen-Bonded Arrays Coupled by Cross-Metathesis

  摘要：

  最近，人们创造出了超分子组装体，作为反应灵敏、可逆和动态的材料。通过模块化方法，我们讨论了含有自互补氢键供体和受体阵列的末端烯烃的可逆交叉甲基化。这些化合物很容易由 2,6-二氨基三嗪或胞嘧啶构建而成，而手性元素则可以由改性氨基酸安装而成。通过这种方法可以获得动态组合库。

  DOI：

  10.1055/s-2007-1000873

文献信息

• THIOPYRANOSE COMPOUND AND METHOD FOR PRODUCING SAME
  申请人：Fujifilm Corporation

  公开号：EP3109246A1

  公开（公告）日：2016-12-28

  There is provided a production method of a thiopyranose compound represented by the following Formula (2) by reacting a compound represented by the following Formula (1) with a sulfur compound. X represents a leaving group. A represents an oxygen atom or a sulfur atom. Each of R1A to R4B, R1B to R4B, and R5 represents a hydrogen atom or a specific substituent.

  本发明提供了一种硫代吡喃糖化合物的生产方法，该化合物由下式（2）代表，其方法是将下式（1）代表的化合物与硫化合物反应。 X 代表离去基团。 A 代表氧原子或硫原子。 R1A至R4B、R1B至R4B和R5各自代表氢原子或特定取代基。
• BETA-KETOACYL-ACP SYNTHASE II VARIANTS
  申请人：CORBION BIOTECH, INC.

  公开号：US20210246434A1

  公开（公告）日：2021-08-12

  Provided are non-natural or variant beta-ketoacyl-acyl carrier protein (ACP) synthase (KAS) II enzymes (KASII), polynucleotides encoding such variant KASII, host cells expressing such variant KASII, oils and oil products produced by such cells, and methods of making and using such variant KASII.
• [EN] CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION<br/>[FR] ANALOGUES DE LA CYCLOSPORINE POUR PRÉVENIR OU TRAITER UNE INFECTION PAR L'HÉPATITE C
  申请人：ENANTA PHARM INC

  公开号：WO2010088573A1

  公开（公告）日：2010-08-05

  The present invention relates to cyclosporin analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporin analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.
• [EN] CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C<br/>[FR] ANALOGUES DE CYCLOSPORINE POUR PRÉVENIR OU TRAITER UNE HÉPATITE C
  申请人：ENANTA PHARM INC

  公开号：WO2015031381A1

  公开（公告）日：2015-03-05

  The present invention relates to novel cyclosporine analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporine analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.